Limited coverage drugs – aclidinium

Last updated on October 7, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	aclidinium
Strength	400 mcg
Form	dry powder for oral inhalation

Special Authority criteria	Approval period
Diagnosis of chronic obstructive pulmonary disease (COPD) AND Failure after a minimum one-month trial of EACH of the Regular Benefit long-acting muscarinic receptor antagonist (LAMA) products¹ Notes: ¹The Regular Benefit LAMA products are the following: tiotropium (Spiriva^® Respimat^®) umeclidinium (Incruse^® Ellipta^®)	Indefinite

Special Authority criteria

Approval period

Diagnosis of chronic obstructive pulmonary disease (COPD)

AND

Failure after a minimum one-month trial of EACH of the Regular Benefit long-acting muscarinic receptor antagonist (LAMA) products¹

Notes:

¹The Regular Benefit LAMA products are the following:

tiotropium (Spiriva^® Respimat^®)
umeclidinium (Incruse^® Ellipta^®)

Indefinite

Practitioner exemptions

None

Special notes

None

Special Authority request form(s)

Log in to eForms
5362 - COPD Form (PDF, 100KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – aclidinium

Practitioner exemptions

Special notes

Special Authority request form(s)